Alberto Pappo is an Oncology physician affiliated with St. Jude Children's Research Hospital. OpenAlex indexes 628 publications with 30,746 citations (h-index 89); ClinicalTrials.gov lists 6 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Pediatric Hematology-Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
262 Danny Thomas Pl
Memphis, TN 381053678
Telephone
901-595-6765Provider last certified this registry record 17 Sept 2024.
Clinical trials
- Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Sponsor: St. Jude Children's Research Hospital
- Tumor Rebiopsy in Children and Adolescents With Recurrent or Progressive Solid Malignancies
Sponsor: St. Jude Children's Research Hospital
- Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
Sponsor: St. Jude Children's Research Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20254 payments
- Alexion Pharmaceuticals, Inc.Program year20248 payments$30,326openpaymentsdata.cms.gov ↗
- Bayer Healthcare Pharmaceuticals Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Hypoxia-inducible Factor Inhibitor100%Welireg100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2022 - NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021
Journal of the National Comprehensive Cancer Network
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Jeffrey Towbin, MD
St. Jude Children's Research Hospital
Raul Ribeiro, MD
St. Jude Children's Research Hospital
Thomas Merchant, DO
St. Jude Children's Research Hospital
Gregory Armstrong, MD
St. Jude Children's Research Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”